Department Of Pediatrics 2
51. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
52. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
53. Management of anaphylaxis due to COVID-19 vaccines in the elderly
54. Management of anaphylaxis due to COVID-19 vaccines in the elderly
55. Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms
56. Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms
57. Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024–2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms
58. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
59. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
60. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
61. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
62. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
63. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
64. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
65. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
66. Methodology and implementation of the WHO European Childhood Obesity Surveillance Initiative (COSI)
67. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021
68. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021
69. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020
70. Socioeconomic inequalities in overweight and obesity among 6- to 9-year-old children in 24 countries from the World Health Organization European region
71. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2·5 air pollution, 1990–2019: an analysis of data from the Global Burden of Disease Study 2019
72. The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation
73. Unmet needs in hereditary angioedema: an international survey of physicians
74. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study
75. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study
76. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study
77. Telemonitoring for acute diseases in general practice as exemplified by COVID-19—a qualitative interview study
78. Global, regional, and national stillbirths at 20 weeks gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021
79. Global, regional, and national stillbirths at 20 weeks gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021
80. Global, regional, and national stillbirths at 20 weeks gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021
81. Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
82. Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
83. Association of Genetic Polymorphisms with Gestational Diabetes in a Kazakh Population: A Case–Control Study
84. A scoping review of mHealth monitoring of pediatric bronchial asthma before and during COVID-19 pandemic
85. Diagnostic Barriers in Children with Immunodeficiencies in Central Asia: A Case-Based Discussion
86. A citizen science approach to develop a digital intervention to reduce HIV stigma and promote HIV self-testing among adolescents and young adults: a mixed methods analysis from Kazakhstan
87. A digital citizen science intervention to reduce HIV stigma and promote HIV testing: a randomized clinical trial among adolescents and young adults in Kazakhstan
88. The Performance and Clinical Applicability of HER2 Digital Image Analysis in Breast Cancer: A Systematic Review
89. Glycemic control in children with type 1 diabetes: Insulin pump therapy versus multiple daily injections
90. Achievements, priorities and strategies in pediatric nephrology in Europe: need for unifying approaches or acceptance of differences?
91. Achievements, priorities and strategies in pediatric nephrology in Europe: need for unifying approaches or acceptance of differences?
92. Achievements, priorities and strategies in pediatric nephrology in Europe: need for unifying approaches or acceptance of differences?
93. Achievements, priorities and strategies in pediatric nephrology in Europe: need for unifying approaches or acceptance of differences?
94. BRAT1–related disorders: phenotypic spectrum and phenotype-genotype correlations from 97 patients
95. BRAT1–related disorders: phenotypic spectrum and phenotype-genotype correlations from 97 patients
96. BRAT1–related disorders: phenotypic spectrum and phenotype-genotype correlations from 97 patients
97. BRAT1–related disorders: phenotypic spectrum and phenotype-genotype correlations from 97 patients
98. BRAT1–related disorders: phenotypic spectrum and phenotype-genotype correlations from 97 patients
99. Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
100. Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
1 2 3 4 7